Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperidone LAI relapse study in schizophrenia
NCT00297388Phase 3Completed
- Sponsor
- Johnson & Johnson
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of risperidone in schizophrenia and schizoaffective disorder (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Time to relapse at 52 weeks. Status: completed.
02
Drugs
risperidone
03
Conditions
schizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NCT00297388.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00297388.